Unlock instant, AI-driven research and patent intelligence for your innovation.
Pharmaceutical composition for treating hemangioma and vascular malformation sclerosis and preparation method and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition and technology of hemangioma, applied in the field of medicine, to achieve the effect of improving embolization efficiency, enhancing therapeutic effect, and strong therapeutic effect
Pending Publication Date: 2020-04-03
SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, when using bleomycin for hemangiomas and vascular malformations, the lifetime dose (<400 mg or 5 mg / kg) is a limitation to reduce the risk of pulmonary fibrosis
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0037] Embodiment 1 A kind of pharmaceutical composition for the treatment of hemangioma and vascular malformation sclerosis
[0040] 1% polidocanol injection to make up the remaining volume
[0041] The above-mentioned bleomycin and 1% polidocanol injection are mixed to obtain the pharmaceutical composition. Inject into syringe 1, use a three-way valve to connect syringe 1 with syringe 2 filled with air, quickly push injection 1 and syringe 2, and pump repeatedly for a total of 20 times to make foam.
Embodiment 2
[0042] Embodiment 2 A kind of pharmaceutical composition for the treatment of hemangioma and vascular malformation sclerosis
[0045] 0.5% Lauromacrogol Injection Supplement the remaining volume
[0046] The above-mentioned bleomycin and 0.5% polidocanol injection are mixed to obtain the pharmaceutical composition. Inject into syringe 1, use a three-way valve to connect syringe 1 with syringe 2 filled with air, quickly push injection 1 and syringe 2, and pump repeatedly for a total of 20 times to make foam.
Embodiment 3
[0047] Example 3 A pharmaceutical composition for the treatment of hemangioma and vascular malformation sclerosis
[0050] 3% polidocanol injection to make up the remaining volume
[0051]The above-mentioned bleomycin and 3% polidocanol injection are mixed to obtain the pharmaceutical composition. Inject into syringe 1, use a three-way valve to connect syringe 1 with syringe 2 filled with air, quickly push injection 1 and syringe 2, and pump repeatedly for a total of 20 times to make foam.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a pharmaceutical composition for treating hemangioma or vascular malformation sclerosis. The pharmaceutical composition at least comprises bleomycin and a foam hardener. The invention further discloses a preparation method and application of the pharmaceutical composition. By using the pharmaceutical composition disclosed by the invention, the retention time of bleomycin ina local focus can be prolonged, and the contact area between bleomycin and a lesion vessel is increased. The embolization efficiency is improved, and a better treatment effect is achieved. Accordingto the composition disclosed by the invention, reduction of single dosage of bleomycin is realized, so that bleomycin plays a stronger treatment role within the limit of the lifetime dosage thereof.
Description
technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for treating hemangioma and vascular malformation sclerosis, a preparation method and application thereof. Background technique [0002] Hemangiomas and vascular malformations are common diseases caused by abnormal proliferation of endothelial cells or congenital malformation of blood vessels or lymphatic vessels. They often appear at birth, usually on the head and face, and can also involve the limbs and trunk. Hemangiomas and vascular malformations affect the appearance and bring a huge burden to the lives of patients. In severe cases, they may even cause organ displacement, bone deformity, and dysfunction. [0003] At present, there are many drugs used in the sclerosing treatment of hemangioma and vascular malformation. The main sclerosing agents include absolute ethanol, bleomycin (Pingyangmycin), foam sclerosing agents (polidocanol, lauromacrogol, tetra...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More